| # | Title | Journal | Year | Citations |
|---|
| 1 | 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure | European Journal of Heart Failure | 2016 | 5,272 |
| 2 | ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 | European Journal of Heart Failure | 2012 | 2,307 |
| 3 | ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008‡ | European Journal of Heart Failure | 2008 | 1,893 |
| 4 | Epidemiology of heart failure | European Journal of Heart Failure | 2020 | 948 |
| 5 | 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines | European Journal of Heart Failure | 2017 | 920 |
| 6 | More ‘malignant’ than cancer? Five-year survival following a first admission for heart failure | European Journal of Heart Failure | 2001 | 885 |
| 7 | Current state of knowledge on Takotsubo syndrome: a Position Statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology | European Journal of Heart Failure | 2016 | 835 |
| 8 | 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure | European Journal of Heart Failure | 2022 | 820 |
| 9 | Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy | European Journal of Heart Failure | 2010 | 787 |
| 10 | Myocardial localization of coronavirus in COVID‐19 cardiogenic shock | European Journal of Heart Failure | 2020 | 783 |
| 11 | Aliskiren, ALTITUDE, and the implications for ATMOSPHERE | European Journal of Heart Failure | 2012 | 737 |
| 12 | State of the art: Using natriuretic peptide levels in clinical practice | European Journal of Heart Failure | 2008 | 691 |
| 13 | EURObservational Research Programme: regional differences and 1‐year follow‐up results of the Heart Failure Pilot Survey (ESC‐HF Pilot) | European Journal of Heart Failure | 2013 | 645 |
| 14 | Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure | European Journal of Heart Failure | 2021 | 630 |
| 15 | Sleep-disordered breathing in patients with symptomatic heart failure A contemporary study of prevalence in and characteristics of 700 patients | European Journal of Heart Failure | 2007 | 624 |
| 16 | The use of diuretics in heart failure with congestion — a position statement from the Heart Failure Association of the European Society of Cardiology | European Journal of Heart Failure | 2019 | 605 |
| 17 | Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine | European Journal of Heart Failure | 2010 | 593 |
| 18 | Exercise training in heart failure: from theory to practice. A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation | European Journal of Heart Failure | 2011 | 580 |
| 19 | Epidemiology and clinical course of heart failure with preserved ejection fraction | European Journal of Heart Failure | 2011 | 569 |
| 20 | Epidemiology and one‐year outcomes in patients with chronic heart failure and preserved, mid‐range and reduced ejection fraction: an analysis of the ESC Heart Failure Long‐Term Registry | European Journal of Heart Failure | 2017 | 568 |
| 21 | Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology | European Journal of Heart Failure | 2018 | 555 |
| 22 | European Society of Cardiology Heart Failure Long‐Term Registry (ESC‐HF‐LT): 1‐year follow‐up outcomes and differences across regions | European Journal of Heart Failure | 2016 | 538 |
| 23 | Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long‐Term Registry | European Journal of Heart Failure | 2013 | 533 |
| 24 | Clinical picture and risk prediction of short‐term mortality in cardiogenic shock | European Journal of Heart Failure | 2015 | 520 |
| 25 | Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review | European Journal of Heart Failure | 2016 | 510 |
| 26 | Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology | European Journal of Heart Failure | 2019 | 490 |
| 27 | The current cost of heart failure to the National Health Service in the UK | European Journal of Heart Failure | 2002 | 471 |
| 28 | Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology | European Journal of Heart Failure | 2016 | 455 |
| 29 | Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology | European Journal of Heart Failure | 2009 | 449 |
| 30 | Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations | European Journal of Heart Failure | 2019 | 446 |
| 31 | Cognitive impairment in heart failure: A systematic review of the literature | European Journal of Heart Failure | 2007 | 445 |
| 32 | Galectin‐3: a novel mediator of heart failure development and progression | European Journal of Heart Failure | 2009 | 434 |
| 33 | Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology | European Journal of Heart Failure | 2018 | 434 |
| 34 | Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology | European Journal of Heart Failure | 2009 | 423 |
| 35 | Essential biochemistry and physiology of (NT-pro)BNP | European Journal of Heart Failure | 2004 | 417 |
| 36 | Treating oxidative stress in heart failure: past, present and future | European Journal of Heart Failure | 2019 | 407 |
| 37 | Concomitant implantation of Impella® on top of veno‐arterial extracorporeal membrane oxygenation may improve survival of patients with cardiogenic shock | European Journal of Heart Failure | 2017 | 402 |
| 38 | Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction | European Journal of Heart Failure | 2007 | 393 |
| 39 | Relation between dose of loop diuretics and outcomes in a heart failure population: Results of the ESCAPE Trial | European Journal of Heart Failure | 2007 | 378 |
| 40 | Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy | European Journal of Heart Failure | 2012 | 369 |
| 41 | Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio‐Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio‐Oncology Society | European Journal of Heart Failure | 2020 | 364 |
| 42 | Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin‐converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF) | European Journal of Heart Failure | 2013 | 358 |
| 43 | Co‐morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey | European Journal of Heart Failure | 2014 | 355 |
| 44 | Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology | European Journal of Heart Failure | 2011 | 350 |
| 45 | Effect of liraglutide, a glucagon‐like peptide‐1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)—a multicentre, double‐blind, randomised, placebo‐controlled trial | European Journal of Heart Failure | 2017 | 343 |
| 46 | EURObservational Research Programme: The Heart Failure Pilot Survey (ESC‐HF Pilot) | European Journal of Heart Failure | 2010 | 340 |
| 47 | Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long‐Term Registry | European Journal of Heart Failure | 2017 | 339 |
| 48 | The validity of a diagnosis of heart failure in a hospital discharge register | European Journal of Heart Failure | 2005 | 338 |
| 49 | Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology | European Journal of Heart Failure | 2007 | 335 |
| 50 | Worsening renal function in patients hospitalised for acute heart failure: Clinical implications and prognostic significance | European Journal of Heart Failure | 2008 | 331 |
